In pancreatic cancer, loss of RUNX3 expression leads to the upregulation of multidrug resistance proteins (MRP), consequently increasing resistance to gemcitabine and adversely affecting patient prognosis [88]. The gene discussed is RUNX3; the disease is familial pancreatic carcinoma.